Bruker (BRKR) announced new orders for advanced nuclear magnetic resonance instrumentation from the New York Structural Biology Center, the University of Delaware and Northwestern University. Supported by the National Institutes of Health and the National Science Foundation, these high-performance systems will enable leading research teams to pursue breakthroughs across a wide range of scientific research, drug discovery and disease biology disciplines. The New York Structural Biology Center ordered an NIH-funded multifield NMR relaxometry system. This advanced relaxometry system will be the first in North America and serves a consortium of nine research institutions in New York State as well as the national community through the NIH-funded Center on Macromolecular Dynamics by NMR spectroscopy. The system consists of a fast NMR sample shuttle system, a magnetic tunnel, and an electromagnetic field cycling coil, all mounted on a 700 MHz superconducting NMR magnet.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- Bruker price target lowered to $40 from $43 at Barclays
- Bruker Positioned for Recovery and Growth Amid Financial Maneuvering and Strategic Initiatives
- Bruker Raises $669.5 Million Through Underwriting Agreement
- Bruker Positioned for Growth with Strategic Financial Moves and Cost Savings Initiatives
- Alphabet jumps after avoiding worst case in antitrust ruling: Morning Buzz